Hostname: page-component-546b4f848f-lx7sf Total loading time: 0 Render date: 2023-06-01T05:27:46.768Z Has data issue: false Feature Flags: { "useRatesEcommerce": true } hasContentIssue false
  • English

Autoimmune Inflammatory Myopathy after Treatment with Ipilimumab

Published online by Cambridge University Press:  02 December 2014

Gary Hunter ,
Chris Voll  and
Christopher A. Robinson
Gary Hunter*
Affiliation:
Department of Neurology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
Chris Voll
Affiliation:
Department of Neurology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
Christopher A. Robinson
Affiliation:
Department of Pathology and Laboratory Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
*
Royal University Hospital, Dept of Neurology, 103 Hospital Drive, Saskatoon, Saskatchewan, S7N 0W8, Canada
Rights & Permissions[Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Brief Communications
Information
Canadian Journal of Neurological Sciences , Volume 36 , Issue 4 , July 2009 , pp. 518 - 520
Copyright
Copyright © The Canadian Journal of Neurological 2009

References

1. Cranmer, LD, Hersh, E. The role of the CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest. 2007;25(7): 613–31.CrossRefGoogle ScholarPubMed
2. Attia, P, Phan, GQ, Maker, AV, Robinson, MR, Quezado, MM, Yang, JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic Tlymphocyte antigen-4. J Clin Oncol. 2005;23(25):6043–53.CrossRefGoogle Scholar
3. Ribas, A, Camacho, LH, Lopez-Berestein, G, Pavlov, D, Bulanhagui, CA, Millham, R, et al. Antitumor activity in melanoma and antiself responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005;23(35):8968–77.CrossRefGoogle Scholar
4. Tchekmedyian, S, Glasby, J, Korman, A, Keler, T, Deo, Y, Davis, T. MDX-010 (human anti-CTLA-4): a phase I trial in malignant melanoma. [abstract] Proc Am Soc Clin Oncol. 2002; 2:56.Google Scholar
5. Phan, GQ, Haworth, LR, Duray, PH, Davis, TA, Rosenberg, SA. Blockade of CTLA-4 with MDX-010 in humans can induce both autoimmunity and cancer regression. [abstract] Proc Am Soc Clin Oncol. 2003; 22: 3424.Google Scholar
6. Maker, AV, Phan, GQ, Attia, P, Yang, JC, Sherry, RM, Topalian, SL, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyteassociated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005, 12(12), 1005–16.CrossRefGoogle Scholar
7. Weber, J. Review: Anti-CTLA-4 Antibody Ipilimumab: case studies of clinical response and immune-related adverse events. The Oncologist. 2007;12:864–72.CrossRefGoogle ScholarPubMed
8. Beck, KE, Blansfield, JA, Tran, KQ, Feldman, AL, Hughes, MS, Royal, RE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte associated antigen 4. J Clin Oncol. 2006;24:2283–9.CrossRefGoogle ScholarPubMed
9. Colucci, F, Bergman, ML, Penha-Goncalves, C, Cilio, CM, Holmberg, D. Apoptosis resistance of nonobese diabetic peripheral lymphocytes linked to the Idd5 diabetes susceptibility region. Proc Natl Acad Sci USA. 1997;94:8670–4.CrossRefGoogle ScholarPubMed
10. Greve, B, Vijayakrishnan, L, Kubal, A, Sobel, RA, Peterson, LB, Wicker, LS, et al. The diabetes susceptibility locus Idd5.1 on mouse chromosome 1 regulates ICOS expression and modulates murine experimental autoimmune encephalomyelitis. J Immunol. 2004;73:157–63.CrossRefGoogle Scholar
11. Ueda, H, Howson, JM, Esposito, L. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature. 2003;423:506–11.CrossRefGoogle ScholarPubMed
12. Wang, HB, Shi, FD, Li, H, Chambers, BJ, Link, H, Ljunggren, HG. Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol. 2001;166 (10):6430–6.CrossRefGoogle ScholarPubMed